All News
Filter News
Found 509 articles
-
Single Cell Analysis Market Size to Worth Around USD 18.89 Bn by 2030
11/28/2022
According to Nova one advisor, the global Single Cell Analysis market size is expected to be worth around USD 18.89 billion by 2030 from valued at USD 4.97 billion in 2022 and poised to grow at a CAGR of 18.22% from 2022 to 2030.
-
NextCure to Present at Upcoming Investor Conferences
11/22/2022
NextCure, Inc. today announced that it will present at the following investor conferences.
-
Cryptococcosis Market Size, Share, Growth, Trends, Consumption, Revenue, Company Analysis and Forecast 2022-2030
11/22/2022
According to Vision Research Reports, the global cryptococcosis market size surpassed at US$ 5.29 Bn in 2021 and to reach US$ 7.79 billion by 2030 with a CAGR of 4.4% from 2022 to 2030.
-
Prominent oncologist to discuss advantages of Oxford BioDynamics’ EpiSwitch CiRT at the 2022 Liquid Biopsy Virtual Summit
11/21/2022
Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for immune health based on the EpiSwitch 3D genomics platform, announces that prominent medical oncologist, Dr. Steven Mamus, a regular user of EpiSwitch CiRT, will be speaking about OBD’s flagship test at the 2022 Liquid Biopsy Virtual Summit, 6 December 2022.
-
GSK has pulled out of its partnership focused on developing T-cell receptor therapeutics for solid tumors with Immatics, the German biotech revealed in its Q3 financial results published Thursday.
-
Alloy Therapeutics inked an antibody discovery deal with Normunity Thursday to advance the latter’s immune normalizers, antibody therapies that boost the body’s natural immune system to fight cancer.
-
mRNA Therapeutics Market Worth USD 52.76 Billion By 2030 | CAGR: 4.7%
11/14/2022
Latest Study on “mRNA Therapeutics Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2022-2030”.
-
Cell Lysis and Disruption Market Size is Expanding USD 7.1 Billion by 2030
11/11/2022
As per Precedence Research, the global cell lysis and disruption market size is expanding around US$ 7.1 billion by 2030 and growing at a CAGR of 6.7% from 2021 to 2030.
-
Scaffold Technology Market Size to Reach Around USD 2.63 Bn by 2030
11/11/2022
The global scaffold technology market was predicted to be USD 1.14 billion in 2021 and is anticipated to reach over USD 2.63 billion by 2030, growing at a CAGR of 9.68% from 2022 to 2030.
-
Viracta Therapeutics Reports Third Quarter 2022 Financial Results and Provides Updates on Clinical Programs
11/10/2022
Viracta Therapeutics, Inc. reported financial results for the third quarter of 2022 and provided an update on recent corporate developments.
-
invIOs presents positive patient data from ongoing Phase 1b trial of APN401 cell therapy in advanced solid tumors at SITC 2022
11/10/2022
invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today presented data from the ongoing clinical trial of its APN401 cell therapy at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2022) in Boston, MA.
-
Respiratory Virus Vaccines Market Size to Hit Around US$ 14.6 Bn by 2030
11/10/2022
According to Vision Research Reports, the global respiratory virus vaccines market size is projected to hit around US$ 14.6 billion by 2030 from US$ 3.2 billion in 2020, growth is expanding at a CAGR of 8.1% from 2021 to 2030.
-
IO Biotech Announces Third Quarter Results for 2022
11/9/2022
IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced financial results for the quarter ending September 30, 2022.
-
IO Biotech Announces an Invited Oral Presentation and Two Poster Presentations with New Preclinical Data for Additional Pipeline Candidates at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
11/9/2022
IO Biotech (Nasdaq: IOBT), IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating anti-cancer therapies based on its proprietary T-win® technology, today announced details of the invited oral presentation and two poster presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting.
-
Generic Drugs Market Size is Expanding Around USD 670.82 Billion by 2030
11/9/2022
The generic drugs market was estimated at USD 439.37 billion in 2022 and is anticipated to reach USD 670.82 billion by 2030, increasing at a CAGR of 5.4% from 2022 to 2030.
-
Immune-Onc Therapeutics Appoints Two New Members to its Board of Directors
11/8/2022
Immune-Onc Therapeutics, Inc. today announced the appointments of Austin L. Gurney, Ph.D. and Barbara J. Klencke, M.D. to the company’s board of directors.
-
Oncolytic Virus Immunotherapy Market Size is Predicted to Hit US$ 2.4 Billion by 2030
11/8/2022
The oncolytic virus immunotherapy market reached value at US$ 108 Million in 2020 and predicted to hit US$ 2.4 billion by 2030 with expanding CAGR of 32% from 2021 to 2030.
-
Legend Biotech Announces Participation in Upcoming November 2022 Investor Conferences
11/4/2022
Legend Biotech Corporation, a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced its participation in the upcoming investor conferences.
-
IO Biotech Announces New Clinical Collaboration with Merck to Evaluate Neoadjuvant and Adjuvant IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) in a Phase 2, Multi-cohort Trial in Patients with Resectable Tumors
11/3/2022
IO Biotech announced that it has entered into a fourth clinical trial collaboration and supply agreement with Merck & Co., Inc., Rahway, NJ, USA, through a subsidiary.
-
Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers
11/2/2022
Transgene (Euronext Paris: TNG) today announces that following an interim analysis of its randomized controlled Phase II clinical study comparing TG4001 in combination with avelumab to avelumab alone in patients with HPV16-positive anogenital tumors (NCT: 03260023), the Independent Data Monitoring Committee (IDMC) has recommended the study continue.